HC Wainwright Issues Negative Forecast for TSE:FRX Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – Research analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of $0.17 for the quarter, down from their previous forecast of $0.26. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q4 2026 earnings at $0.22 EPS, Q3 2027 earnings at $0.36 EPS, Q4 2027 earnings at $0.42 EPS and FY2027 earnings at $1.33 EPS.

Separately, B. Riley Financial upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Strong Buy”.

Fennec Pharmaceuticals Price Performance

Shares of Fennec Pharmaceuticals stock opened at C$8.33 on Tuesday. The business has a 50-day moving average of C$10.57 and a 200 day moving average of C$11.14. Fennec Pharmaceuticals has a 12 month low of C$7.02 and a 12 month high of C$13.83. The stock has a market capitalization of C$284.58 million, a price-to-earnings ratio of -23.80 and a beta of 3.01.

Insider Buying and Selling at Fennec Pharmaceuticals

In other news, Director Rostislav Christov Raykov sold 10,349 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of C$10.69, for a total transaction of C$110,630.81. Following the sale, the director owned 2,709,294 shares of the company’s stock, valued at approximately C$28,962,352.86. This represents a 0.38% decrease in their ownership of the stock. Corporate insiders own 16.20% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.